Philips grows orders and sales, holds 2026 outlook amid cost pressure

Transcript intelligence

What changed

In Q1 2026, order intake rose 6% and comparable sales increased 4%; adjusted EBITDA margin expanded 40 basis points to 9%. Management maintained its full-year 2026 outlook. Compared with the prior call’s confident outlook, current discussion puts more emphasis on cost inflation, China demand and the pace of margin delivery.

Guidance delta

Full-year 2026 guidance was maintained: comparable sales growth of 3–4.5%, adjusted EBITDA margin of 12.5–13%, and free cash flow of €1.3–1.5 billion.

Key takeaways

• Order intake grew 6% and comparable sales rose 4%, with Personal Health and North America cited as strengths.
• Adjusted EBITDA margin increased 40 basis points to 9% despite higher tariffs and cost inflation.
• Management reiterated full-year 2026 guidance and cited productivity, bill-of-material reductions and selective pricing as mitigation actions.
• The innovation pipeline includes helium-free MRI, AI-enabled cardiac MR and spectral CT; the 3.0T helium-free MRI is expected to require regulatory clearance in 2027.

Management priorities

• Use AI-enabled productivity programs, bill-of-material reductions and selective pricing to mitigate cost pressure.
• Expand the imaging, cardiac MR and enterprise monitoring/informatics offerings.
• Develop consumer-health distribution and retail listings in the U.S.
• Pursue regulatory clearance for 3.0T helium-free MRI, which management expects in 2027.